GNCC Capital, Inc. (GNCP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNCC Capital, Inc. (GNCP) trades at $0.00 with AI Score 48/100 (Grade C). GNCC Capital, Inc. , through its subsidiary, focuses on producing and selling cannabis CBD pharmaceutical grade oils. Market cap: $8.71M, Sector: Basic materials.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for GNCP: GNCP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNCP against Basic Materials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GNCP: the 1 perspectives are evenly split.
How is this calculated? →GNCC Capital, Inc. (GNCP) Materials & Commodity Exposure
GNCC Capital, Inc. operates in the basic materials sector, specifically focusing on the production and distribution of cannabis CBD pharmaceutical grade oils in Colombia and Latin America. The company faces significant competition and regulatory hurdles in the evolving cannabis market.
What Is the Investment Thesis for GNCP?
GNCC Capital, Inc. presents a speculative investment opportunity within the cannabis CBD pharmaceutical sector in Latin America. The company's focus on pharmaceutical-grade CBD oils positions it to potentially capture a segment of the market demanding high-quality products. However, the company's small market capitalization of $8.71M and negative beta of -38.68 indicate high volatility and sensitivity to market movements. Growth depends on successful navigation of regulatory hurdles, securing distribution partnerships, and scaling production efficiently. Investors should carefully consider the risks associated with investing in a micro-cap company operating in a rapidly evolving and highly regulated industry.
Based on FMP financials and quantitative analysis
GNCP Key Highlights
- GNCC Capital, Inc. operates in the cannabis CBD pharmaceutical sector through its subsidiary BioCann Pharma S.A.S.
- The company focuses on producing and selling cannabis CBD pharmaceutical grade oils.
- GNCC Capital distributes its products through channels in Colombia and throughout Latin America.
- The company is based in Las Vegas, Nevada.
- GNCC Capital has a market capitalization of $8.71M.
Who Are GNCP's Competitors?
GNCP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| WPM Wheaton Precious Metals Corp. | $115.28 | -0.38% | $52.35B | 69 |
| ORLA Orla Mining Ltd. | $10.17 | -0.10% | $3.82B | 69 |
| OR OR Royalties Inc. | $30.82 | -1.97% | $5.78B | 68 |
| FNV Franco-Nevada Corporation | $214.72 | -1.31% | $41.41B | 66 |
| AAUC Allied Gold Corporation | $24.24 | -1.46% | $3.05B | 56 |
| ORZCF Orezone Gold Corporation | $1.77 | +2.69% | $963.00M | 57 |
| RMLRF Ramelius Resources Limited | $2.16 | +2.76% | $4.09B | 57 |
| YRBAF Yorbeau Resources Inc. | $0.04 | +0.00% | $19.02M | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNCP's Key Strengths?
- Focus on pharmaceutical-grade CBD oils.
- Distribution network in Colombia and Latin America.
- Potential for growth in the expanding cannabis market.
- Expertise in cannabis cultivation and processing.
What Are GNCP's Weaknesses?
- Small market capitalization.
- Dependence on a single subsidiary.
- Limited product diversification.
- Negative beta indicating high volatility.
What Could Drive GNCP Stock Higher?
- Potential regulatory changes in Latin American countries regarding cannabis legalization.
- Increasing acceptance of CBD products for medical use.
- Expansion of distribution network in Latin America.
What Are the Key Risks for GNCP?
- Regulatory setbacks in the cannabis industry.
- Intense competition from established pharmaceutical companies.
- Fluctuations in the price of cannabis and CBD.
- Dependence on a single subsidiary for revenue generation.
- Negative beta indicating high volatility.
What Are the Growth Opportunities for GNCP?
- Expansion into New Latin American Markets: GNCC Capital can expand its distribution network to other Latin American countries, capitalizing on the increasing acceptance of CBD products in the region. The Latin American cannabis market is projected to experience significant growth, offering opportunities for GNCC Capital to increase its market share and revenue. Timeline: Within the next 3-5 years.
- Development of New CBD Products: GNCC Capital can invest in research and development to create new CBD-based pharmaceutical products, catering to specific medical conditions and patient needs. This diversification can enhance the company's product portfolio and attract a wider customer base. The global CBD market is expected to continue expanding, driven by increasing awareness of its potential health benefits. Timeline: Ongoing.
- Strategic Partnerships with Pharmaceutical Companies: GNCC Capital can form strategic alliances with established pharmaceutical companies to co-develop and distribute its CBD products. These partnerships can provide access to established distribution channels, regulatory expertise, and marketing resources, accelerating market penetration. The pharmaceutical industry is increasingly exploring the potential of cannabis-based therapies. Timeline: Within the next 2-3 years.
- Vertical Integration of Supply Chain: GNCC Capital can integrate its supply chain by acquiring or establishing its own cultivation and processing facilities. This vertical integration can improve quality control, reduce costs, and ensure a consistent supply of raw materials. The cannabis industry is increasingly emphasizing the importance of supply chain management. Timeline: Ongoing.
- Focus on Pharmaceutical-Grade Quality: By maintaining a strict focus on producing pharmaceutical-grade CBD oils, GNCC Capital can differentiate itself from competitors and attract customers seeking high-quality products. The pharmaceutical sector demands rigorous quality standards, providing a barrier to entry for less sophisticated producers. Timeline: Ongoing.
What Opportunities Does GNCP Have?
- Expansion into new Latin American markets.
- Development of new CBD-based pharmaceutical products.
- Strategic partnerships with pharmaceutical companies.
- Vertical integration of supply chain.
What Threats Does GNCP Face?
- Regulatory uncertainty in the cannabis industry.
- Intense competition from established pharmaceutical companies and other cannabis producers.
- Fluctuations in the price of cannabis and CBD.
- Potential for negative publicity or product recalls.
What Are GNCP's Competitive Advantages?
- Focus on pharmaceutical-grade CBD oil production.
- Established distribution channels in Colombia and Latin America.
- Expertise in navigating the regulatory landscape of the cannabis industry.
- Potential for brand recognition and customer loyalty through consistent product quality.
What Does GNCP Do?
GNCC Capital, Inc., based in Las Vegas, Nevada, operates through its subsidiary, BioCann Pharma S.A.S., to produce and distribute cannabis CBD pharmaceutical grade oils. The company focuses on serving the Latin American market, primarily Colombia, through established distribution channels. GNCC Capital aims to capitalize on the growing demand for CBD products in the pharmaceutical sector within the region. The company's business model centers around cultivating, processing, and distributing high-quality CBD oils that meet pharmaceutical standards. GNCC Capital navigates the complex regulatory landscape of the cannabis industry in Latin America to ensure compliance and market access. The company's success hinges on its ability to maintain consistent product quality, secure distribution partnerships, and adapt to evolving regulations in the cannabis market.
What Products and Services Does GNCP Offer?
- Produces cannabis CBD pharmaceutical grade oils.
- Sells products through distribution channels.
- Operates primarily in Colombia and throughout Latin America.
- Focuses on the pharmaceutical sector.
- Cultivates and processes CBD oils.
- Navigates the regulatory landscape of the cannabis industry.
How Does GNCP Make Money?
- Cultivation and processing of cannabis plants to extract CBD oil.
- Manufacturing of pharmaceutical-grade CBD oil products.
- Distribution of products through established channels in Colombia and Latin America.
- Revenue generation through the sale of CBD oil products to distributors and end-users.
What Industry Does GNCP Operate In?
GNCC Capital, Inc. operates within the evolving cannabis industry, specifically targeting the CBD pharmaceutical sector in Latin America. The global cannabis market is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis for medical and recreational purposes. However, the industry faces challenges such as regulatory uncertainty, intense competition, and varying consumer preferences. GNCC Capital's success depends on its ability to navigate these challenges and establish a strong presence in its target markets. The competitive landscape includes both established pharmaceutical companies and emerging cannabis producers.
Who Are GNCP's Key Customers?
- Pharmaceutical companies seeking high-quality CBD ingredients.
- Distributors of pharmaceutical products in Colombia and Latin America.
- Patients seeking CBD-based treatments for various medical conditions.
- Retailers of health and wellness products.
Company Profile
GNCC Capital, Inc. operates in the Gold industry within the Basic Materials sector. It is headquartered in Las Vegas, US. The company is led by CEO Nicolaas Edward Blom. GNCP has traded publicly since 2009.
GNCP Valuation & Market Position
With a $8.71M market cap, GNCC Capital, Inc. sits in the micro-cap segment of the market. Relative to its peer group, GNCP's quantitative score of 48/100 is below the peer average of 66/100.
ROE 358%Key Financial Metrics
Return on equity for GNCC Capital, Inc. stands at 357.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.5%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.9%, the inverse of the P/E and a quick read on earnings relative to price.
GNCP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in GNCC's future, which can positively influence market perception.
- Community sentiment has shifted favorably, with discussions highlighting potential growth opportunities in the energy sector.
- There is increasing interest in GNCC's strategic partnerships that could enhance its market position and operational capabilities.
- The company's recent initiatives to diversify its portfolio align with broader market trends, appealing to socially conscious investors.
Bear Case
- Concerns about the overall volatility in the small-cap market may lead to cautious sentiment around GNCC.
- Some community members express skepticism about the sustainability of GNCC's growth, citing past performance issues.
- Negative news cycles surrounding the energy sector could overshadow GNCC's potential, affecting investor confidence.
- Recent regulatory challenges in the industry may pose risks to GNCC's operational plans, leading to bearish sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GNCP Latest News
-
Premier Development & Investment, Inc. to Amend Articles in Order to Capitalize and Eliminate Certain Long Term Liabilities and All Short Term Loans Totaling no Less Than $29 Million
Yahoo! Finance: GNCP News · Jun 3, 2026
-
Premier Development & Investment, Inc. Eliminates $6 Million in Outstanding Convertible Loan Notes
Yahoo! Finance: GNCP News · May 21, 2026
-
Premier Development & Investment, Inc. Files Q1 Report and Advises Upon Further Material Issues
Yahoo! Finance: GNCP News · May 20, 2026
GNCP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNCP.
Price Targets
Wall Street price target analysis for GNCP.
GNCP MoonshotScore
What does this score mean?
The MoonshotScore rates GNCP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Premier Development & Investment, Inc. to Amend Articles in Order to Capitalize and Eliminate Certain Long Term Liabilities and All Short Term Loans Totaling no Less Than $29 Million
Premier Development & Investment, Inc. Eliminates $6 Million in Outstanding Convertible Loan Notes
Premier Development & Investment, Inc. Files Q1 Report and Advises Upon Further Material Issues
GNCP OTC Market Information
GNCP trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
Common Questions About GNCP (Basic Materials)
What does GNCC Capital, Inc. do?
GNCC Capital, Inc., through its subsidiary BioCann Pharma S.A.S., focuses on the production and distribution of pharmaceutical-grade CBD oils. The company operates primarily in Colombia and throughout Latin America, targeting the growing demand for CBD products in the pharmaceutical sector. GNCC Capital aims to establish itself as a reliable supplier of high-quality CBD oils, navigating the complex regulatory landscape of the cannabis industry in the region. The company's success depends on its ability to maintain consistent product quality, secure distribution partnerships, and adapt to evolving regulations.
What are the main risks for GNCP?
GNCC Capital, Inc. faces several risks inherent in the cannabis industry, including regulatory uncertainty, intense competition, and fluctuations in the price of cannabis and CBD. The company's small market capitalization and dependence on a single subsidiary also pose significant risks. Furthermore, GNCC Capital's negative beta indicates high volatility, making it susceptible to market downturns. Investors should carefully consider these risks before investing in GNCP.
What are the key factors to evaluate for GNCP?
GNCC Capital, Inc. (GNCP) holds an AI score of 48/100 (low). Not financial advice.
How frequently does GNCP data refresh on this page?
GNCP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNCP's recent stock price performance?
GNCC Capital, Inc. (GNCP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on pharmaceutical-grade CBD oils. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNCP overvalued or undervalued right now?
Valuing GNCC Capital, Inc. (GNCP) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GNCP?
Before investing in GNCC Capital, Inc. (GNCP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNCP to a portfolio?
Key strength of GNCC Capital, Inc. (GNCP): Focus on pharmaceutical-grade CBD oils. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- AI analysis is pending.